Novel Therapeutics for the Treatment of Multiple Sclerosis (MS)
- Detailed Technology Description
- Our scientists have identified a protein‐protein coupling between the glutamate R2 (GluR2) ‐ α‐amino‐3‐hydroxy‐5‐methylisoxazole‐4‐propionic acid (AMPA) receptor and the extracellular protein glyceraldehyde‐3‐phosphate dehydrogenase (GAPDH) as a novel target for the treatment of the neurodegenerative effects of multiple sclerosis (MS). By characterizing the protein‐protein (GluR2‐GAPDH complex) interaction we have developed a peptide that interferes with this coupling thereby leading to the development of a breakthrough therapy capable of delivering enhanced affinity, efficacy, and a superior side effect profile.
- *Abstract
-
- Country/Region
- USA
For more information, please click Here
